US FDA approves Purdue Pharma’s Zurnai auto-injector
Zurnai is indicated for treating suspected or known opioid overdose in adults and pediatric patients aged 12 years and older. It is not a substitute for emergency medical
Persist AI and Nivagen have joined forces to co-develop an advanced AI-driven manufacturing process for long-acting injectable (LAI) drugs.
The territories include Japan, South Korea, and several Southeast Asian countries, including Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. CBT-001 is an investigational emulsified nintedanib ophthalmic formulation
Ackermans & van Haaren spearheaded the investment round, with participation from both new investors including Driehaus Capital Management and Quest for Growth. Current investors namely BioGeneration Ventures, Capricorn